Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886811 | 0.92 | HTR2B (0.41) | NPY5RHTR2BPDE10A | |
| SCHEMBL2885063 | 0.92 | HTR2B (0.41) | NPY5RHTR2BPDE10A | |
| SCHEMBL2881817 | 0.91 | NPY5R (0.46) | NPY5RUSP30ALKBH3PDE10A | |
| SCHEMBL2878853 | 0.89 | NPY5R (0.52) | NPY5RHTR2BALKBH3 | |
| SCHEMBL2886640 | 0.82 | HTR2B (0.40) | NPY5RHTR2BPDE10A | |
| SCHEMBL2881815 | 0.82 | HTR2B (0.40) | NPY5RHTR2BPDE10A | |
| SCHEMBL2878848 | 0.80 | HTR2B (0.48) | NPY5RHTR2B | |
| Hydrochloric Acid SCHEMBL2885612 | 0.76 | NPY5R (0.48) | NPY5RUSP30HTR2BALKBH3PDE10A | |
| SCHEMBL2886433 | 0.73 | NPY5R (0.48) | NPY5RUSP30HTR2BALKBH3 | |
| SCHEMBL2885222 | 0.71 | BACE1 (0.52) | NPY5RUSP30HTR2BPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | claimed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | claimed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | claimed |
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | NPY1R, NPY2R, NPY5R | NPY5R 3/4885USP30 3878/4885HTR2B 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.